JP2022029409A - Antiviral composition - Google Patents

Abstract

To provide an antiviral composition having excellent virus inactivating action.SOLUTION: An antiviral composition contains one or more selected from (A) a cationic surfactant, (B) an anionic surfactant, and (C) a bactericide.SELECTED DRAWING: None

Description

The present invention relates to an antiviral composition.

In recent years, an infectious disease (COVID-19) caused by the new coronavirus (SARS-CoV-2) has been rampant worldwide, causing a pandemic. The spread of viral infectious diseases caused by influenza and norovirus has been repeatedly prevalent, and when infected with these viruses, severe symptoms such as high fever, severe vomiting, and diarrhea develop, so consumers' awareness of infection prevention. Is very expensive. In addition to droplet infection by inhaling droplets such as coughing and sneezing of infected people, the infection route of the virus includes the infected person's spit, door knobs with runny nose, smartphones, and fingers touching textile products such as clothing. Contact infection is known due to contact with mucous membranes such as the nose and eyes. In this way, viral infectious diseases are a very important preventive method for hand and environmental antiviral measures, and the Ministry of Economy, Trade and Industry and NITE (National Institute of Technology and Evaluation) have introduced various components such as surfactants. Has been reported to be effective against the new coronavirus (Non-Patent Document 1).

Effectiveness evaluation of alternative disinfection method for new coronavirus (final report), National Institute of Technology and Evaluation (NITE), Reiwa June 2

The present invention has been made in view of the above circumstances, and relates to providing an antiviral composition having an excellent virus inactivating effect.

As a result of diligent studies to achieve the above object, the present inventors have selected one or more selected from (A) cationic surfactant, (B) anionic surfactant, and (C) bactericidal agent. An antiviral composition having an excellent virus inactivating effect including the present invention has been found, and the present invention has been made.

That is, the present invention provides the following antiviral composition.
<1> (A) Cationic surfactant,
(B) Anionic surfactant,
(C) An antiviral composition containing one or more selected from bactericides.
<2> (A) A cationic surfactant represented by the following formula (1),
R1R2R3R4N + X- (1)
(In the formula, R1, R2, R3, and R4 are independently selected and have 1 to 24 carbon atoms.
Linear or branched alkyl group, branched alkenyl group, benzyl group, or-(AO)
) NR, where A is one or more selected from a linear or branched alkylene group having 1 to 4 carbon atoms, and n represents the average number of added moles of (AO), which is 0.1 to 20. R is H or CH3, and X- is a monovalent anion of an inorganic or organic acid or an equivalent polyvalent anion. )
(B) One or more selected from higher fatty acids, polyoxyethylene alkyl ether sulfates, ether carboxylic acids, amino acid-based surfactants, and olefin sulfonates (C) Selected from ethanol, isopropylmethylphenol, and salicylic acid 1
More than seeds
The antiviral composition according to <1>.
<3> (A) A monoalkyltrimethylammonium salt having 8 to 18 carbon atoms, a dialkyldimethylammonium salt having 4 to 18 carbon atoms, and an alkylbenzyldimethylammonium salt having 8 to 18 carbon atoms. , One or more alkyl sulfate ions (B) One or more selected from laurate, myristate, palmitate, stearate, polyoxyethylene alkyl ether sulfate <1> or <2> The antiviral composition of the description.
<4> Dodecyltrimethylammonium chloride and ethanol, potassium laurate and / or potassium myristate and isopropylmethylphenol, sodium polyoxyethylylene lauryl ether sulfate and isopropylmethylphenol,
The antiviral composition according to <1> or <2> or <3> selected from the combination of.
<5> The antiviral composition according to <1> or <2> or <3> or <4> for skin or hard surface or textile product treatment.

According to the present invention, it is possible to provide an antiviral composition having an excellent virus inactivating effect.

The antiviral composition of the present invention is an antiviral composition containing one or more selected from (A) cationic surfactant, (B) anionic surfactant, and (C) bactericidal agent.

<(A) Cationic Surfactant>
The cationic surfactant of the component (A) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, monoalkyltrimethylammonium salt, alkoxyalkyltrimethylammonium salt, dialkyldimethylammonium salt, alkylbenzyldimethylammonium salt, alkyldimethylamine and its salt, alkoxyalkyldimethylamine and its salt, alkylamide amine and its salt and the like can be mentioned.

Specific examples of the cationic surfactant of the component (A) include stearyltrimethylammonium chloride, cetyltrimethylammonium chloride, behenyltrimethylammonium chloride, hexadecyltrimethylammonium chloride, dodecyltrimethylammonium chloride, and stearyltrimethylammonium bromide. , Distearyldimethylammonium chloride, Dioleyldimethylammonium chloride, Didecyldimethylammonium chloride, Tetramethylammonium chloride, Hexadecyltrimethylammonium metosulfate salt, Didecyldimethylammonium metosulfate, benzalkonium chloride, Laurate acetate amide butylguanidine , Myristic acid amide butyl guanidine acetate, palmitate amide butyl guanidine acetate, distearyldimethylammonium sulfate, stearylethyldihydroxyethylammonium ethylsulfate, N-palm oil fatty acid L-arginine ethyl DL-pyrrolidone carboxylate, dimethylamino stearate Ethylamide, stearic acid dimethylaminopropylamide, stearic acid diethylaminoethylamide, stearic acid diethylaminopropylamide, stearic acid dipropylaminoethylamide, stearic acid dipropylaminopropylamide, palmitate dimethylaminoethylamide, palmitate dimethylaminopropyl Examples thereof include amide, stearic acid dimethylaminoethylamide, stearic acid dimethylaminopropylamide, behenic acid dimethylaminoethylamide, and behenic acid dimethylaminopropylamide. These may be used alone or in combination of two or more.

Among these, as the cationic surfactant of the component (A), stearyltrimethylammonium chloride, cetyltrimethylammonium chloride, dodecyltrimethylammonium chloride, stearyltrimethylammonium bromide, disstearyldimethylammonium chloride, dioleyldimethylammonium chloride , Didecyldimethylammonium chloride, hexadecyltrimethylammonium metosulfate salt, didecyldimethylammonium metosulfate, benzalkonium chloride are preferred, and dodecyltrimethylammonium chloride, didecyldimethylammonium chloride, hexadecyltrimethylammonium metosulfate salt are particularly preferred. ..

As the component (A), a commercially available product may be used, or an appropriately synthesized product may be used. Examples of the commercially available product include: Trade name: Lipocard T-800 (stearyltrimethylammonium chloride, manufactured by Lion Specialty Chemicals Co., Ltd.), trade name: Catinal CTC-70ET (cetyltrimethylammonium chloride, Toho Chemical Industry Co., Ltd.) (Manufactured by Co., Ltd.), Product name: Lipocard 12-37W (Dodecyltrimethylammonium chloride, manufactured by Lion Specialty Chemicals Co., Ltd.), Product name: Catinal HTB-70ET (Stearyltrimethylammonium bromide, Toho Chemicals Co., Ltd.) Product name: Lipocard 210-80E (didecyldimethylammonium chloride, manufactured by Lion Specialty Chemicals Co., Ltd.), Product name: Lipocard 16-30MSK (hexadecyltrimethylammonium metosulfate salt, Lion Specialty. Chemicals Co., Ltd.) and the like. These may be used alone or in combination of two or more.

The content of the component (A) is preferably 0.01 to 1% by mass, more preferably 0.01 to 0.5% by mass, based on the whole composition. If it is 0.01% by mass or more, the virus inactivating effect is excellent, and if it is 1% by mass or less, the object is not sticky or irritating.

<(B) Anionic surfactant>
The anionic surfactant of the component (B) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, an alkyl sulfonate, an alkyl sulfate, an alkyl sulfosuccinate, an acylated amino acid salt, etc. N-acyl-N- such as polyoxyalkylene alkyl ether sulfate (as the alkylene moiety, polyoxyethylene and polyoxypropylene are preferable, polyoxyethylene is more preferable), alkylbenzene sulfonate, coconut oil fatty acid methyl taurine salt and the like. Methyl taurine salt, olefin sulfonate, higher fatty acid ester sulfonate, alkyl ether acetate, polyoxyethylene alkyl ether acetate, potassium laurate, potassium myristate, potassium palmitate, potassium stearate, sodium laurate, myristin Fatty acid soap such as sodium acid, sodium palmitate, sodium stearate, alkyl phosphate ester salt, N-lauroyl glutamate, N-acylglutamate such as N-palmitoyl glutamate, N-lauroyl-N-ethylglycine salt Examples thereof include N-acyl-N-carboxyalkyl-glycine salt such as N-acyl-N-carboxyalkyl-glycine salt, acyl sarcosine salt such as N-lauroyl sarcosin salt, N-acyl-β-alanine salt such as N-myristoyl-β-alanine salt and the like. These may be used alone or in combination of two or more. Examples of the counter ion of these salts include alkali metal salts, alkaline earth metal salts, ammonium salts, alkanolamine salts and the like.

Among these, polyoxyethylene alkyl ether sulfate, olefin sulfonate, alkyl sulfonate, and fatty acid soap are preferable, and polyoxyethylene lauryl ether sodium sulfate, potassium laurate, potassium myristate, and potassium palmitate are particularly preferable. ..

The polyoxyethylene alkyl ether sulfate preferably has 10 to 24 carbon atoms as the alkyl group portion, more preferably 12 to 14 carbon atoms, and the average number of moles of ethylene oxide added (hereinafter, also referred to as “EO”). 1 to 3 is preferable, and 1 to 2 is more preferable. The salt of the polyoxyethylene alkyl ether sulfate is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include alkali metals, ammonium and alkanolamines. Among these, alkali metals and ammonium are preferable, sodium and ammonium are more preferable, and sodium is particularly preferable.

As the polyoxyethylene alkyl ether sulfate, a commercially available product may be used, or an appropriately synthesized product may be used. Examples of the commercially available product include trade name: Emar 170J (sodium polyoxyethylene lauryl ether sulfate (EO: 1), manufactured by Kao Co., Ltd.), and trade name: Sinoline SPE-1250 (sodium polyoxyethylene lauryl ether sulfate (EO)). : 2), manufactured by Shin Nihon Rika Co., Ltd.), trade name: Teikapol NE1270 (polyoxyethylene lauryl ether sodium sulfate (EO: 3), manufactured by Teika Co., Ltd.) and the like. These may be used alone or in combination of two or more. Among these, the trade name: Sinoline SPE-1250 (polyoxyethylene lauryl ether sodium sulfate (EO: 2), manufactured by Shin Nihon Rika Co., Ltd.) is preferable from the viewpoint of good foaming and fineness of foam.

As the fatty acid soap, a commercially available product may be used, or, for example, a fatty acid synthesized by neutralizing it with an alkali such as potassium hydroxide may be used.

The content of the component (B) is preferably 0.2 to 10% by mass, more preferably 3 to 10% by mass, based on the whole composition. If it is 0.2% by mass or more, the virus inactivating effect is excellent, and if it is 10% by mass or less, the object is not sticky and is not slimy at the time of rinsing.

<(C) Fungicide>
The disinfectant for the component (C) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, ethanol, isopropyl alcohol, isopropylmethylphenol, chlorhexidine gluconate, salicylic acid, sodium hypochlorite and the like can be selected. Can be mentioned. These may be used alone or in combination of two or more. Among these, ethanol, isopropylmethylphenol and salicylic acid are preferable.

If the content of the component (C) is ethanol, it is preferably 5 to 60% by mass, more preferably 5 to 50% by mass, based on the whole composition. When the mass is 5% or more, the virus inactivating effect is excellent, and when the mass is 60% or less, the non-irritating effect is excellent. In the case of isopropylmethylphenol and salicylic acid, 0.01 to 1% by mass, more preferably 0.1 to 1% by mass, of the total composition. If the mass is 0.01% or more, the virus inactivating effect is excellent, and if the mass is 1% or less, the virus is not irritating.

<Other ingredients>
The other components are not particularly limited, and other components may be contained in addition to the components (A) to (C) as long as the effects of the present invention are not impaired. The other components are not particularly limited and may be appropriately selected depending on the intended purpose. For example, a cationic surfactant other than the component (A), an anionic surfactant other than the component (B), and the like. Bactericides other than the component (C), nonionic surfactants, anionic polymers, nonionic polymers, polyols, salt, inorganic salts such as glazed glass, organic salts, moisturizers such as polyglyceryl monolaurate, propylene glycol, tonics. Agents, solubilizers, antioxidants such as BHT and α-tocopherols, viscosity regulators such as fatty acid diethanolamide, UV absorbers, protein derivatives, animal and plant extracts, pyrocton olamine, anti-surfactants such as zincpyrythion, glycyrrhizin Anti-inflammatory agents such as dipotassium acid, benzoic acid or salts thereof, parabens, preservatives such as Kason CG, pH regulators such as citric acid and triethanolamine, emulsions, hydrotropes, lower alcohols, vitamins, volatilization Examples thereof include acid oils, hydrophobic solvents, dilutable solvents such as purified water, pigments and fragrances. These may be used alone or in combination of two or more.

<Manufacturing method>
The method for producing the antiviral composition is not particularly limited and may be appropriately selected depending on the intended purpose. The component (A) to the component (C) and the other components are mixed and prepared. be able to. The device for preparing the antiviral composition is not particularly limited and may be appropriately selected depending on the intended purpose. For example, it is provided with a plurality of stirring blades (propeller, turbine, dispenser, etc.) capable of shearing and total mixing. Examples include a stirrer.

<Container>
The container is not particularly limited and may be appropriately selected depending on the intended purpose. For example, a pump dispenser container, a spray container, a former pump container, a tube container, a bag-shaped container and the like can be mentioned.
Examples of the material of the pump dispenser container include polyethylene, polypropylene, polyethylene terephthalate, polystyrene, polyvinyl chloride, ethylene-vinyl alcohol resin, acrylonitrile-styrene resin, ABS resin, polyamide, glass and the like, and a single layer or 2 It is preferable to use a combination of layers or more. For example, a pump dispenser container manufactured by Yoshino Kogyosho Co., Ltd. with a nozzle diameter (inner diameter) of 3.5 mm and a discharge rate of 3 mL can be mentioned.
Examples of the spray container include an aerosol spray container, a trigger spray container (direct pressure type or accumulator type), a dispenser spray container, and the like. Examples of the aerosol spray container include those described in JP-A-9-3441 and JP-A-9-58765. Examples of the propellant include LPG (liquefied propane gas), DME (dimethyl ether), carbon dioxide gas, nitrogen gas and the like, and these may be used alone or in combination of two or more. good. Examples of the trigger spray container include those described in JP-A-9-268473, JP-A-9-256272, JP-A-10-76196 and the like. Examples of the dispenser spray container include those described in JP-A-9-256272.
Examples of the former pump container include a non-gas type foam discharge container. The non-gas type foam discharge container is not particularly limited as long as the liquid detergent composition and air can be passed through the porous membrane body and discharged in a foamed state, and can be appropriately selected according to the purpose. For example, a squeeze former container capable of discharging foam by manually pressing the bottle body, a former pump container capable of discharging foam by pushing down the nozzle portion, and the like can be mentioned. As such a former pump container, a product manufactured by Daiwa Seikan Co., Ltd., a product manufactured by Yoshino Kogyosho Co., Ltd., or the like can be used.
The non-gas type foam discharge container usually has a porous membrane for forming foam (preferably a plastic material such as nylon, polyester, or polyolefin), and the liquid skin cleaning agent composition is the porous membrane. Bubbles are formed by passing through the body with air. The mesh of the porous membrane body is not particularly limited and may be appropriately selected depending on the intended purpose. For example, 100 mesh or more is preferable, 100 to 400 mesh is more preferable, and 200 mesh is more preferable from the viewpoint of foam elasticity. ~ 350 mesh is more preferable. The number of porous membranes is not particularly limited and may be appropriately selected depending on the intended purpose, but 2 to 4 are preferable from the viewpoint of improving foam performance. More specifically, the former pump containers described in JP-A-7-315463, JP-A-8-230961, and JP-A-2005-193972 can be preferably used.

<Use>
The antiviral composition of the present invention is not particularly limited and may be appropriately selected depending on the intended purpose. For example, it can be used as a composition for skin such as hand soap, body soap, cleansing foam, makeup remover, for hard surfaces or for treating textile products.
The method for using the antiviral composition of the present invention on a hard surface or a textile product is not particularly limited. The textile product may be dipped in the composition and then air-dried, or the composition may be stored in a spray container and sprayed on a hard surface or the textile product with the composition and then air-dried or wiped off. In particular, the composition is stored in a spray container and hard because it is easy to carry out at home and the required amount of the composition can act only on the hard surface or the part of the textile product that is of concern. The method of spraying on the surface or textile products is preferable.
The present invention also relates to a virus inactivating method comprising applying an antiviral composition to a virus on the skin, a hard surface, or a fiber, but the term "application" as used herein refers to the antivirus of the present invention. It includes dropping, applying, spraying or the like a stock solution of the composition or a diluted solution thereof to contact or soak the site to be applied, a hard appearance, a textile product, or then wipe it off.
The object of using the antiviral composition of the present invention for hard surfaces or textile products is not particularly limited, but for example, a dining table, a cooking table, a kitchen counter, a floor (floor / vinyl), a child's product (toys / baby chair).・ Play mats, etc.), pet supplies (toys, cages, toilets, etc.), furniture, cupboards, mirrors, windows, Y-shirts, T-shirts, polo shirts, blouses, chino bread, suits, slacks, skirts, jackets, coats, knits, jeans , Pajamas, table cloths, luncheon mats, curtains, cushions, cushions, sofas, pillowcases, sheets, bed pads, pillows, duvets, bedspreads, blankets, mattresses, shoes, toilet mats, bath mats, entrance mats, carpets, rugs, Examples include carpets.
Viruses that can be inactivated by the antiviral composition of the present invention include both enveloped and non-enveloped types. The viruses that can be inactivated by the antiviral composition of the present invention are double-stranded DNA virus, single-stranded DNA virus, double-stranded RNA virus, single-stranded (+) RNA virus, and single-stranded (-). RNA virus and reverse transcription virus can be mentioned. For example, viruses belonging to the family Caliciviridae, Orthomyxoviridae, Coronaviridae, Herpesviruses and the like can be mentioned.
The virus inactivating effect of the antiviral composition of the present invention may be any effect as long as it exerts an effect of removing or reducing the infectious or proliferative ability of the virus.

Hereinafter, the present invention will be described in more detail based on Examples, but the present invention is not limited to the following Examples. In addition, the content of each component described in an Example is a value converted into a pure content.

(Examples 1 to 28)
The composition and content of the antiviral composition shown in Table 1 below were prepared by the following method. That is, the component (C) and a part of purified water were mixed, and the component (A), 3 sodium methylglycine acetate, zinc sulfate, polyether-modified silicon, and a fragrance were added and mixed uniformly. Then, while stirring, dilute sulfuric acid was added, the pH was adjusted to 4.5 using a pH meter (pH meter F-52, HORIBA, Ltd.), and the remaining purified water was added.

(Examples 29 to 44)
The composition and content of the antiviral composition shown in Table 2 below were prepared by the following method. That is, the component (B) and a part of purified water were uniformly mixed at 70 ° C. using a paddle type stirrer. While continuing stirring, component (C), sorbitol, and propylene glycol were added and dissolved, and then the mixture was cooled to 25 ° C. while stirring. Then, while stirring, potassium hydroxide was added, the pH was adjusted to 10.0 using a pH meter (pH meter F-52, HORIBA, Ltd.), and the remaining purified water was added.

The "virus inactivating effect" of the obtained antiviral compositions of Examples 1 to 44 was evaluated as follows. The results are shown in Tables 1 to 3.

<Virus inactivation test method 1>
The antiviral compositions of Examples and Comparative Examples were allowed to act on the virus, and the virus inactivating effect 1 of the Examples and Comparative Example compositions was evaluated by the TCID50 method.
(1) Test virus Influenza A virus (H1N1 A / PR / 8/34)
(2) Preparation of virus solution Influenza A virus was ingested into the chorioallantoic cavity of a growing chicken egg, statically cultured in an oviduct, and the serous solution was collected and purified by density gradient centrifugation to obtain a virus solution. ..
(3) Inactivation test and viral load measurement
(I) 0.45 mL of the composition of Example or Comparative Example and 0.05 mL of the virus solution prepared above were mixed at room temperature and reacted for 30 seconds (time of action).
(Ii) SCDLP (Soybean-Casein Digest Broth with Lecithin & Polysorbate) medium was added to the influenza A virus solution obtained in (i) above, and the reaction was stopped by diluting 10-fold. The obtained liquid was used as a stock solution and diluted 10-fold with MEM (minimal essential medium). The obtained liquid was used as a stock solution and diluted 10-fold with PBS.
(Iii) Cells for infecting the virus were prepared in a 96-well plate.
(Iv) 100 μL of the undiluted solution or diluted solution prepared in (ii) above was implanted in cells prepared in a 96-well plate in (iii), and then the infectious titer was measured according to the TCID50 method (based on the Behrens-Karber method).
In the above methods (i) to (iv), the action time was set to 0 seconds, and the one using MEM instead of the composition was tested, and the infectious titer was measured. The value obtained by subtracting the logarithm of the infectious titer of each composition from the logarithm of the infectious titer was defined as the "infectious titer logarithm decrease value". Based on the infectivity logarithm reduction value, the virus inactivating ability of each composition was evaluated according to the following criteria. In addition, as a preliminary test, it was confirmed that all cells grew by evaluating the virus-free sample by the above inactivation test method.
<Evaluation criteria>
⊚: Evaluation virus infection logarithm reduction value is 4 or more
〇: Evaluation virus infectivity logarithm reduction value is 3 or more and less than 4 Δ: Evaluation virus infection value logarithm reduction value is 1 or more and less than 3 ×: Evaluation virus infection value logarithm reduction value is less than 1.

<Virus inactivation test method 2>
The antiviral compositions of Examples and Comparative Examples were allowed to act on the virus, wiped with a cloth, and then the virus inactivating effect 2 of the Examples and Comparative Example compositions was evaluated by the TCID50 method.
(1) Test virus Influenza A virus (H1N1 A / PR / 8/34) and feline calicivirus (Feline Calicivirus F9)
(2) Preparation of virus solution (a) Influenza A virus solution
Influenza A virus was ingested into the serous allantois cavity of a growing chicken egg, statically cultured in an incubator, and the serous solution was collected and purified by density gradient centrifugation to obtain a virus solution.
(B) Feline calicivirus solution
Feline calicivirus (FCV) F9 strain was inoculated into cultured cells, washed with PBS (-), and then statically cultured in a serum-free eagle MEM medium in an oviduct. When the cytopathic effect occurred on all cells, the culture solution and cells were collected, and the supernatant obtained by centrifugation was used as a virus solution.
(3) Inactivation test and viral load measurement
(I) 0.1 mL of the virus solution prepared above was applied to the polypropylene test piece and dried at room temperature.
(Ii) 0.9 mL of the composition of Example or Comparative Example was applied to the test piece of (i) above, and after 1 minute (acting time), the test piece was wiped off once with a cloth.
(Iii) The reaction was stopped by adding EMEM (Eagle's Minimal Essential Medium) to the test piece obtained in (ii) above and diluting it 51-fold. The obtained liquid was used as a stock solution and diluted 10-fold with EMEM.
(Iv) Cells for infecting the virus were prepared in 96-well plates.
(V) 100 μL of the undiluted solution or diluted solution prepared in (iii) above was implanted in cells prepared in a 96-well plate in (iv), and then the infectious titer was measured according to the TCID50 method (based on the Behrens-Karber method).
In the above methods (i) to (v), the action time was set to 0 minutes, the composition was not applied, and the wiping operation was not performed, and the infectious titer was measured. The value obtained by subtracting the logarithm of the infectious titer of each composition from the logarithm of the infectious titer was defined as the "infectious titer logarithm decrease value". Based on the infectivity logarithm reduction value, the virus inactivating ability of each composition was evaluated according to the following criteria. In addition, as a preliminary test, it was confirmed that all cells grew by evaluating the virus-free sample by the above inactivation test method.
<Evaluation criteria>
⊚: Infection logarithm reduction value of 4 or more for both evaluated viruses
〇: Infection rate logarithm reduction value of 2 types of evaluation virus is 3 or more and less than 4, or only one of the evaluation viruses has an infection value logarithm reduction value of 4 or more. Less than or only one of the evaluated viruses has an infection logarithm reduction value of 2 or more and less than 3.
X: Of the two evaluated viruses, one has an infectious logarithmic reduction value of less than 1, and the other has an infectious logarithmic reduction value of less than 2.

Virus removal spray

Virus removal spray

Virus removal spray

Foam hand soap

Foam hand soap

Body Soap

The details of the various components used in the Examples and the Comparative Examples are shown in Table 7 below.

The anti-virus composition of the present invention has an excellent virus inactivating effect, and is, for example, a composition for skin, hard surface or textile product treatment such as hand soap, body soap, cleansing foam and makeup remover. It is preferably used as.

Claims (5)

(A) Cationic surfactant,
(B) Anionic surfactant,
(C) An antiviral composition containing one or more selected from bactericidal agents. (A) A cationic surfactant represented by the following formula (1),
R1R2R3R4N + X- (1)
(In the formula, R1, R2, R3, and R4 are each independently selected and are a linear or branched alkyl group having 1 to 24 carbon atoms, a branched alkenyl group, a benzyl group, or-(AO) nR, where A is. One or more selected from a linear or branched alkylene group having 1 to 4 carbon atoms, n represents the average number of added moles of (AO), 0.1 to 20, and R is H or CH3. X- is a monovalent anion of an inorganic acid or an organic acid or an equivalent polyvalent anion.)
(B) One or more selected from higher fatty acids, polyoxyethylene alkyl ether sulfates, ether carboxylic acids, amino acid-based surfactants, olefin sulfonates (C) One or more selected from ethanol, isopropylmethylphenol, salicylic acid The antiviral composition according to claim 1. (A) A monoalkyltrimethylammonium salt having 8 to 18 carbon atoms, a dialkyldimethylammonium salt having 4 to 18 carbon atoms, and an alkylbenzyldimethylammonium salt having 8 to 18 carbon atoms. The antivirus according to claim 1 or 2, wherein one or more (B) laurates, myristates, palmitates, stearate, and one or more selected from polyoxyethylene alkyl ether sulfates, which are ions. Composition. The antiviral composition according to claim 1-3, which is selected from a combination of dodecyltrimethylammonium chloride and ethanol, potassium laurate and / or potassium myristate and isopropylmethylphenol, polyoxyethylene lauryl ether sodium sulfate and isopropylmethylphenol. The antiviral composition according to claim 1 to 4, for skin or hard surface or for treating textile products.